Selective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumab
Jill MV Petkau, Bertus Eksteen Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada Abstract: Inflammatory bowel disease (IBD) encompasses a cluster of different disease phenotypes which are broadly classified into ulcerative colitis and Croh...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-03-01
|
Series: | Biologics : Targets & Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/selective-biologics-for-ulcerative-colitis-and-crohn39s-disease-ndash--peer-reviewed-article-BTT |
id |
doaj-16d54277c0ca45cd9a766de82cb513b8 |
---|---|
record_format |
Article |
spelling |
doaj-16d54277c0ca45cd9a766de82cb513b82020-11-24T23:43:27ZengDove Medical PressBiologics : Targets & Therapy1177-54912016-03-012016Issue 1335225912Selective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumabPetkau JMEksteen BJill MV Petkau, Bertus Eksteen Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada Abstract: Inflammatory bowel disease (IBD) encompasses a cluster of different disease phenotypes which are broadly classified into ulcerative colitis and Crohn's disease. Disease pathogenesis is driven by abnormal host immune responses to their resident gut microbiome in genetically susceptible individuals. Clinical disease features and outcomes are heterogenous and not unexpected as over 163 genetic loci are associated with disease susceptibility, and there are great variability in environmental exposures. Despite this variability, there has been relatively few efficacious therapies for particularly moderate-to-severe IBD. Treatment has been dominated by antitumor necrosis alpha agents with significant success but equally potentially serious adverse events. Therapeutic targeting of leucocyte trafficking has emerged as a viable alternative therapy, with vedolizumab being the lead compound. This review focuses primarily on its biological function as a selective gut immunotherapy, its safety and efficacy, and its emerging role as a mainstream therapy in managing IBD. Keywords: adhesion molecule antagonist, anti-α4β7 integrin, inflammatory bowel disease, leukocyte trafficking, monoclonal antibody, selective gut immunotherapy, tumor necrosis factor alphahttps://www.dovepress.com/selective-biologics-for-ulcerative-colitis-and-crohn39s-disease-ndash--peer-reviewed-article-BTTVedolizumabUlcerative ColitisCrohn's disease |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Petkau JM Eksteen B |
spellingShingle |
Petkau JM Eksteen B Selective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumab Biologics : Targets & Therapy Vedolizumab Ulcerative Colitis Crohn's disease |
author_facet |
Petkau JM Eksteen B |
author_sort |
Petkau JM |
title |
Selective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumab |
title_short |
Selective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumab |
title_full |
Selective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumab |
title_fullStr |
Selective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumab |
title_full_unstemmed |
Selective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumab |
title_sort |
selective biologics for ulcerative colitis and crohn's disease – clinical utility of vedolizumab |
publisher |
Dove Medical Press |
series |
Biologics : Targets & Therapy |
issn |
1177-5491 |
publishDate |
2016-03-01 |
description |
Jill MV Petkau, Bertus Eksteen Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada Abstract: Inflammatory bowel disease (IBD) encompasses a cluster of different disease phenotypes which are broadly classified into ulcerative colitis and Crohn's disease. Disease pathogenesis is driven by abnormal host immune responses to their resident gut microbiome in genetically susceptible individuals. Clinical disease features and outcomes are heterogenous and not unexpected as over 163 genetic loci are associated with disease susceptibility, and there are great variability in environmental exposures. Despite this variability, there has been relatively few efficacious therapies for particularly moderate-to-severe IBD. Treatment has been dominated by antitumor necrosis alpha agents with significant success but equally potentially serious adverse events. Therapeutic targeting of leucocyte trafficking has emerged as a viable alternative therapy, with vedolizumab being the lead compound. This review focuses primarily on its biological function as a selective gut immunotherapy, its safety and efficacy, and its emerging role as a mainstream therapy in managing IBD. Keywords: adhesion molecule antagonist, anti-α4β7 integrin, inflammatory bowel disease, leukocyte trafficking, monoclonal antibody, selective gut immunotherapy, tumor necrosis factor alpha |
topic |
Vedolizumab Ulcerative Colitis Crohn's disease |
url |
https://www.dovepress.com/selective-biologics-for-ulcerative-colitis-and-crohn39s-disease-ndash--peer-reviewed-article-BTT |
work_keys_str_mv |
AT petkaujm selectivebiologicsforulcerativecolitisandcrohn39sdiseasendashclinicalutilityofvedolizumab AT eksteenb selectivebiologicsforulcerativecolitisandcrohn39sdiseasendashclinicalutilityofvedolizumab |
_version_ |
1725501568095092736 |